RAMM Pharma (XCNQ:RAMM) 5-Year EBITDA Growth Rate: -2.80% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RAMM Pharma 5-Year EBITDA Growth Rate?

RAMM Pharma XCNQ:RAMM 5-Year EBITDA Growth Rate is -2.80% as of Apr. 2026. The stock has 4 warning signs investors should review.

RAMM Pharma's EBITDA per Share for the three months ended in Apr. 2026 was C$-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 25.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of RAMM Pharma was 25.90% per year. The lowest was -169.90% per year. And the median was -29.50% per year.

RAMM Pharma  (XCNQ:RAMM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

RAMM Pharma 5-Year EBITDA Growth Rate Related Terms

XCNQ:RAMM vs ZTS: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAMM Pharma 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where RAMM Pharma's 5-Year EBITDA Growth Rate falls into.


RAMM Pharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of -2.80% mean?
RAMM Pharma (XCNQ:RAMM) has a 5-Year EBITDA Growth Rate of -2.80% as of Apr. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for RAMM Pharma and its competitors.
Is RAMM Pharma's 5-Year EBITDA Growth Rate too high?
RAMM Pharma's current 5-Year EBITDA Growth Rate is -2.80%.
How does RAMM Pharma's 5-Year EBITDA Growth Rate compare to ZTS?
RAMM Pharma's 5-Year EBITDA Growth Rate of -2.80% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for RAMM Pharma and its competitors. RAMM Pharma's current 5-Year EBITDA Growth Rate is -2.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current 5-Year EBITDA Growth Rate is -2.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current 5-Year EBITDA Growth Rate is -2.80% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RAMM Pharma Business Description

Address 82 Richmond Street E, Toronto, ON, CAN, M5C 1P1
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.